This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Hypertension Optimal Treatment study

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • aim - to measure the effect of incremental blood pressure on morbidity and mortality

  • study design - 18 790 people randomised to treatment aimed at reducing blood pressure to 90, 85 or 80 mm Hg. Treatment consisted of a calcium channel blocker (taken by approximately 80% of patients), plus, if necessary, an ACE inhibitor (40%), a beta blocker (30%) and a diuretic (20%). Also patients were randomised to aspirin prophylaxis or placebo. The mean age of patients in the trial was 61.5 y and the mean diastolic pressure 105 mm Hg

  • Results
    • lowest risk of major cardiovascular events occurred at a mean blood pressure of 139/83 mmHg
    • lowest risk of cardiovascular mortality occurred at mean blood pressure of 140/87 mmHg
    • lowest risk of stroke when blood pressure lower than 142/80mm Hg
    • aspirin treatment reduced major cardiovascular events by 15%; aspirin treatment also reduced all myocardial infarction by 36%; aspirin treatment did not reduce the risk of stroke

  • Conclusions
    • first evidence for an overall benefit of low-dose aspirin in hypertensive patients
    • analysis of results based on achieved blood pressure indicates that optimal blood pressure is about 140/85 mmHg

Reference:

  • Prescriber (1998), 9(16), 23.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.